Blog
RSS FeedPosted by Michael Wonder on 16 Oct 2023
Health economic assessment of Enhertu in breast cancer
13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions. ...
Posted by Michael Wonder on 05 Jul 2023
TLV is tasked with carrying out health economic assessments of new drugs against cancer
4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...
Posted by Michael Wonder on 18 Jun 2023
Health economic assessment of Carvykti in the treatment of multiple myeloma
16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...
Posted by Michael Wonder on 14 Jun 2023
Health economic assessment of Pluvicto in advanced prostate cancer
12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan). ...
Posted by Michael Wonder on 04 Apr 2023
TLV reconsiders the subsidy of Lumykras (sotorasib)
4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...
Posted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
Posted by Michael Wonder on 25 May 2022
Health economic assessment of Trodelvy in advanced triple negative breast cancer
23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 12 Feb 2022
Health economic assessment of Jemperli in endometrial cancer
11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is ...
Posted by Michael Wonder on 07 Feb 2022
Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract
7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab). ...
Posted by Michael Wonder on 11 Oct 2021
Health economic assessment of Poteligeo in the treatment of mycosis fungoides or Sézary syndrome
11 October 2021 - TLV has produced a health economic assessment for the regions for the drug Poteligeo (mogamulizumab). ...
Posted by Michael Wonder on 06 Sep 2021
Health economic assessment of Sarclisa in multiple myeloma
6 September 2021 - TLV has produced a health economic assessment for the regions for the drug Sarclisa (isatuximab) in combination ...
Posted by Michael Wonder on 19 Aug 2021
EndoPredict for breast cancer - the company chose not to participate with data
19 August 2021 - In November 2020, Myriad Genetics chose to refrain from participating in a health economic assessment of EndoPredict. ...